TFF Pharmaceuticals announces new partnership with Emory University, BARDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Partnership Announcement: TFF Pharmaceuticals has partnered with Emory University and BARDA to explore the conversion of an mRNA-based antiviral into a dry powder formulation.
Benefits of New Formulation: The new formulation aims for precise inhalational delivery, enhanced stability, and easier distribution without requiring cold-chain storage.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
